Drugs / Alocyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05909709 | Apr 2024 → Oct 2026 expected | osteoarthritis, spine | Alimorad Farshchian | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909709 ↗ |
| Modality | Cell therapy | “Alocyte is a cellular, minimally manipulated product derived from umbilical cord blood.” NCT05909709 ↗ |
| Route | Other | “administered intra-facet into a single facet joint” NCT05909709 ↗ |